miRagen reports Phase I data of systemic microRNA therapy in CTCL

miRagen Therapeutics Inc. (NASDAQ:MGEN) reported interim data from 23 evaluable patients with mycosis fungoides-type cutaneous T cell lymphoma (CTCL) in the second part of an open-label, U.S

Read the full 270 word article

How to gain access

Continue reading with a
two-week free trial.